Corindus Vascular Robotics (Formerly known as Corindus)
309 Waverley Oaks Road
124 articles with Corindus Vascular Robotics (Formerly known as Corindus)
Corindus Vascular Robotics, Inc. announced that it will release financial and business results for the first quarter of 2018 after the close of trading on Tuesday, May 8, 2018.
Corindus Announces $25 Million Private Placement of Series A Convertible Preferred Shares and Warrants
Douglas Braunstein to Join Board of Directors
Corindus Vascular Robotics Inc. reported financial results for its fourth quarter and year ended December 31, 2017.
Mr. Tobin currently serves on a number of Boards, including TransMedics, Inc., Oxford Immunotec Global PLC, and Globus Medical, Inc.
Corindus Receives FDA Clearance for First Automated Robotic Movement in technIQ™ Series for CorPath GRX Platform
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath GRX platform.
Delray Beach Medical Center Performs First Robotic-Assisted Peripheral Vascular Intervention Using Corindus CorPath® GRX System Following FDA Clearance
Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, announced today the successful completion of the first robotic-assisted peripheral vascular intervention procedure using the recently FDA-cleared CorPath GRX System.
Corindus to Co-Sponsor Courses at Multiple Leading Healthcare Institutions on Value-based Interventional Procedural Training
Corindus announced it will co-sponsor courses at multiple leading hospitals to educate interventional cardiologists on transradial access techniques and robotic-assisted vascular interventions.
Preliminary and unaudited revenue for fourth quarter 2017 is expected to be between $4.0 million and $4.2 million..
Corindus to Participate With Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary Interventions Remote Treatment Capabilities
Corindus announced today that it is working with Mayo Clinic in a preclinical study about use of telestenting. Telestenting, or the remote robotic treatment for percutaneous coronary intervention (PCI).
Corindus will partner with Apex Heart Institute to develop a Global Center of Excellence to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).
Corindus Partners With Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians
Houston Methodist DeBakey Heart & Vascular Center has launched the first vascular robotic program in the Houston area with the installation of two CorPath® GRX Systems.
Revenue for the third quarter of 2017 was $2.4 million compared to $0.7 million for the same period in the prior year.
Corindus to Feature CorPath GRX System at the Transcatheter Cardiovascular Therapeutics 2017 Conference
The symposium, chaired by Sunil V. Rao, M.D., FSCAI of Duke University Medical Center and featuring faculty from leading cardiovascular institutions, will focus on the benefits of radial access combined with robotic assistance for PCI.
Corindus Vascular Robotics today announced that it will release financial and business results for the second quarter of 2017 after the close of trading on Tuesday, November 7, 2017.
Corindus Vascular Robotics, Inc. announced today that it will incorporate the HeartFlow FFRct Analysis in a case series of robotic-assisted percutaneous coronary intervention (PCI) procedures with the CorPath GRX System to evaluate the feasibility and utility of clinical decision support.
Corindus Vascular Robotics Announces 100th Robotic-Assisted PCI Procedure Performed Using 2nd Generation CorPath GRX System